NOBILI, STEFANIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.283
EU - Europa 9.945
AS - Asia 6.082
SA - Sud America 898
AF - Africa 174
OC - Oceania 123
Continente sconosciuto - Info sul continente non disponibili 2
Totale 29.507
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.117
RU - Federazione Russa 2.784
PL - Polonia 2.757
IT - Italia 1.872
SG - Singapore 1.749
CN - Cina 1.397
HK - Hong Kong 904
BR - Brasile 723
VN - Vietnam 679
IE - Irlanda 673
KR - Corea 510
SE - Svezia 481
DE - Germania 320
FI - Finlandia 283
FR - Francia 254
IN - India 194
GB - Regno Unito 172
JO - Giordania 125
JP - Giappone 122
AU - Australia 120
UA - Ucraina 90
BD - Bangladesh 79
ID - Indonesia 79
CA - Canada 77
AR - Argentina 75
TR - Turchia 64
NL - Olanda 50
ES - Italia 46
MX - Messico 45
CH - Svizzera 42
IQ - Iraq 42
ZA - Sudafrica 37
CI - Costa d'Avorio 35
AT - Austria 34
EC - Ecuador 32
BE - Belgio 30
NG - Nigeria 28
MA - Marocco 18
PK - Pakistan 18
CO - Colombia 17
EG - Egitto 14
VE - Venezuela 13
CL - Cile 12
PH - Filippine 12
TH - Thailandia 12
DO - Repubblica Dominicana 11
PY - Paraguay 11
SA - Arabia Saudita 11
IR - Iran 9
GR - Grecia 8
TN - Tunisia 8
UZ - Uzbekistan 8
AE - Emirati Arabi Uniti 7
AL - Albania 7
ET - Etiopia 7
LB - Libano 7
LT - Lituania 7
MY - Malesia 7
PE - Perù 7
DZ - Algeria 6
IL - Israele 6
KE - Kenya 6
SY - Repubblica araba siriana 6
KZ - Kazakistan 5
RO - Romania 5
BB - Barbados 4
BJ - Benin 4
CR - Costa Rica 4
CZ - Repubblica Ceca 4
JM - Giamaica 4
NP - Nepal 4
OM - Oman 4
SC - Seychelles 4
TW - Taiwan 4
AZ - Azerbaigian 3
BH - Bahrain 3
BO - Bolivia 3
DK - Danimarca 3
GE - Georgia 3
HN - Honduras 3
LV - Lettonia 3
NO - Norvegia 3
NZ - Nuova Zelanda 3
PA - Panama 3
SK - Slovacchia (Repubblica Slovacca) 3
SV - El Salvador 3
TT - Trinidad e Tobago 3
UY - Uruguay 3
BG - Bulgaria 2
BT - Bhutan 2
HU - Ungheria 2
MN - Mongolia 2
NI - Nicaragua 2
PR - Porto Rico 2
PS - Palestinian Territory 2
QA - Qatar 2
RS - Serbia 2
AG - Antigua e Barbuda 1
AM - Armenia 1
AO - Angola 1
Totale 29.485
Salva come PNG Salva come JPEG
Città #
Warsaw 2.744
Santa Clara 2.438
Ashburn 1.427
Singapore 1.260
Fairfield 884
Hong Kong 739
Dublin 671
Chandler 669
Seoul 494
San Jose 486
Woodbridge 433
Cambridge 385
Seattle 380
Houston 377
Milan 341
Wilmington 319
Beijing 305
Hefei 272
Ann Arbor 225
The Dalles 211
Ho Chi Minh City 204
Buffalo 182
Altamura 179
Florence 174
Princeton 173
Lawrence 168
Lauterbourg 159
Dallas 152
Los Angeles 150
Rome 145
Council Bluffs 142
Hanoi 141
Boston 135
Jacksonville 133
Moscow 133
Helsinki 121
Tokyo 114
Melbourne 105
Mumbai 104
New York 94
Munich 91
Boardman 89
Shanghai 87
Medford 69
San Diego 67
Bremen 63
Kent 63
São Paulo 58
Jakarta 53
Paris 53
Clifton 49
Falls Church 47
Turku 42
Turin 41
Naples 40
Redondo Beach 38
Izmir 37
London 36
Abidjan 35
Bern 34
Haiphong 34
Phoenix 34
Da Nang 33
Dong Ket 32
Norwalk 31
Bologna 30
Dearborn 30
Frankfurt am Main 29
Toronto 29
Palermo 28
Orem 27
Vienna 27
Chicago 26
Abuja 25
Hillsboro 24
Bari 23
Guangzhou 23
Johannesburg 23
Brussels 22
Figino 22
Belo Horizonte 21
Rio de Janeiro 21
Lappeenranta 20
Bengaluru 19
Brooklyn 18
Catania 17
Miano 17
Denver 16
Genoa 16
Montreal 16
West Jordan 16
Barcelona 15
Dhaka 15
Stockholm 15
Baghdad 14
Chennai 14
Hải Dương 14
San Francisco 14
Tianjin 14
Amsterdam 13
Totale 19.937
Salva come PNG Salva come JPEG
Nome #
2D-DIGE analysis of ovarian cancer cell responses to cytotoxic gold compounds 410
Exploring the biochemical mechanisms of cytotoxic gold compounds: a proteomic study. 389
Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies. 360
RNA sequencing reveals a distinct transcriptomic profile predictive of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 354
Proteomic Analysis of Ovarian Cancer Cell Responses to Cytotoxic Gold Compounds 353
In vitro assessment of antibody-conjugated gold nanorods for systemic injections 351
The Inhibitory Effects of HYDAMTIQ, a Novel PARP Inhibitor, on Growth in Human Tumor Cell Lines With Defective DNA Damage Response Pathways. 340
High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer. 339
Antiproliferative effects of two gold(I)-N-heterocyclic carbene complexes in A2780 human ovarian cancer cells: A comparative proteomic study 339
Farmaci antineoplastici - Farmaci inibitori della trasduzione del segnale - Farmaci inibitori di protein chinasi 336
Natural compounds for cancer treatment and prevention 331
Thymidylate synthase expression and genotype have no major impact on the clinical outcome of colorectal cancer patients treated with 5-fluorouracil 329
Emerging drugs in refractory colorectal cancer 327
Proteomic analysis of A2780/S ovarian cancer cell response to the cytotoxic organogold(III) compound Aubipy(c.) 319
Pharmacokinetic study of gemcitabine, given as prolonged infusion at fixed dose rate, in combination with cisplatin in patients with advanced non-small-cell lung cancer. 316
Druggable Targets in Pancreatic Adenocarcinoma 310
HLA-G 3'UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment 308
Proteomic analysis of the cytotoxic effects induced by the organogold(III) complex Aubipyc in cisplatin-resistant A2780 ovarian cancer cells: further evidence for the glycolytic pathway implication 305
Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic Acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy. 296
A case report of eyelid Merkel cell carcinoma occurring under treatment with nivolumab for a lung adenocarcinoma. 286
MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin 279
Analysis of Gene Expression Profiles Reveals Novel Correlations With the Clinical Course of Colorectal Cancer 263
Selection and characterization of a human ovarian cancer cell line resistant to auranofin 252
Epigenetics and chemoresistance in colorectal cancer: An opportunity for treatment tailoring and novel therapeutic strategies 250
Replacement of the Thiosugar of Auranofin with Iodide Enhances the Anticancer Potency in a Mouse Model of Ovarian Cancer 247
Association of the HLA-G 3′UTR polymorphisms with colorectal cancer in Italy: a first insight 241
RNA sequencing reveals PNN and KCNQ1OT1 as predictive biomarkers of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 239
A transcriptomic profile predicts clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 236
Chemistry and Biology of Two Novel Gold(I) Carbene Complexes as Prospective Anticancer Agents 234
Fluoropyrimidine-related toxicity in gastrointestinal cancer patients. Assessment of risk factors. 227
Cellular pharmacology of gemcitabine. 222
Editorial: multidrug resistance in cancer: pharmacological strategies from basic research to clinical issues. 220
A Clinical-Genetic Score to Identify Surgically Resected Colorectal Cancer Patients Benefiting From an Adjuvant Fluoropyrimidine-Based Therapy. 216
MOLECULAR CHARACTERIZATION OF ESTABLISHED HUMAN COLON CARCINOMA CELL LINES (HCT-8) MADE RESISTANT TO 5-FLUOROURACIL BY DIFFERENT SELECTION SCHEDULES 214
Exploring the biochemical mechanisms of cytotoxic gold compounds: a proteomic study. 214
Treatment of locally advanced hepatocellular carcinoma by hepatic intra-artery chemotherapy: a pilot study. 211
Exploratory Genome-Wide Association Analysis to Identify Pharmacogenetic Determinants of Response to R-CHOP in Diffuse Large B-Cell Lymphoma 206
Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression 206
D13Global gene expression profile reveals a distinct transcriptomic profile predictive of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 206
Identification Of Pharmacogenomic Markers Of Clinical Efficacy In A Dose-Dense Therapy Regimen (R-Chop14) In Diffuse Large B Cell Lymphoma 205
THE IMPACT OF GENETIC POLYMORPHISMS ON R-CHOP EFFICACY IN DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS: AN INTERIM ANALYSIS OF A MULTICENTER PROSPECTIVE PHARMACOGENETIC STUDY 203
Chronic inflammation in urothelial bladder cancer 203
Role of Genetic Polymorphisms on Response to R-CHOP regimen in Diffuse Large B-cell Lymphoma Patients: an Interim Analysis of a Multicenter Prospective Pharmacogenetic Study 196
Structure, solution chemistry, antiproliferative actions and protein binding properties of non-conventional platinum(II) compounds with sulfur and phosphorus donors. 195
Trabectedin in combination with pegylated liposomal doxorubicin in patients with ovarian tumors 193
Global gene expression profile reveals a distinct transcriptomic profile predictive of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 193
Role of genetic polymorphisms on R-CHOP efficacy in diffuse large B-cell lymphoma patients: an interim analysis of a multicenter prospective pharmacogenetics study. 190
Artificial Intelligence Predictive Models of Response to Cytotoxic Chemotherapy Alone or Combined to Targeted Therapy for Metastatic Colorectal Cancer Patients: A Systematic Review and Meta-Analysis 190
Pharmacogenetics: Implementing personalized medicine 188
Gold(III) complexes with 2-substituted pyridines as experimental anticancer agents: Solution behavior, reactions with model proteins, antiproliferative properties 185
Clinical outcomes and safety of patients treated with NAb-Paclitaxel plus Gemcitabine in metastatic pancreatic cancer: the NAPA study 183
The molecular mechanisms of antimetastatic ruthenium compounds explored through DIGE proteomics 181
Role of genetic polymorphisms on R-CHOP efficacy in diffuse large B-cell lymphoma patients: an interim analysis of a multicenter prospective pharmacogenetics study. 180
PNN and KCNQ1OT1 can predict the efficacy of adjuvant fluoropyrimidine-based chemotherapy in colorectal cancer patients 178
Correlation between thymidylate synthase (TS) mRNA expression and TS gene promoter polymorphisms in primary colorectal cancer patients 175
Adverse drug reactions in oncoLogy: intEnsive monitoring program on drug toXicity of biotechnological medicatioNs anD taRget therapies in Oncologic patientS - the ALEXANDROS observational study 174
Identification of potential pharmacogenomic markers of clinical efficacy of 5-fluorouracil in colorectal cancer 174
The clinical role of PIK3CA mutations in colorectal cancer 167
Establishment and characterization of a new spontaneously immortalized ER-/PR-/HER2+ human breast cancer cell line, DHSF-BR16 167
Prognostic factors in primary and iterative surgery of colorectal liver metastases 166
Analisi dell'espressione di geni coinvolti nella resistenza al 5-fluorouracile nel carcinoma colorettale 166
Pharmacological modulation of protein kinase C for overcoming drug resistance in colorectal cancer. Preliminary results of in vitro studies. 165
Synthesis, Structural Characterization, Solution Behavior, and in Vitro Antiproliferative Properties of a Series of Gold Complexes with 2-(2'-Pyridyl)benzimidazole as Ligand: Comparisons of Gold(III) versus Gold(I) and Mononuclear versus Binuclear Derivatives 164
Vinorelbine in non-small cell lung cancer: Real-World data from a single institution experience 164
TAS-102 in gastric cancer: Development and perspectives of a new biochemically modulated fluroropyrimidine drug combination 163
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer. 162
Identification of pharmacogenomic markers of 5-fluorouracil-based chemotherapy in colorectal cancer 161
Administering gemcitabine as fixed-dose-rate infusion in combination with cisplatin, potentially effective target plasma concentrations are achieved in patients with advanced non-small cell lung cancer 160
Size dependent biological profiles of PEGylated gold nanorods 159
In vitro cell growth inhibitory effects of HYDAMTIQ, a novel PARP inhibitor, on human tumor cell lines with defective DNA damage response pathways 158
Platinum-based chemotherapy in metastatic prostate cancer: what possibilities? 158
Genotype-Driven Phase I Study of Irinotecan Administered in Combination With Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer 158
Snail immunohistochemical overexpression correlates to recurrence risk in non-muscle invasive bladder cancer: results from a longitudinal cohort study 158
Immune checkpoint inhibitors in pre-treated gastric cancer patients: Results from a literature-based meta-analysis 158
Postoperative chemotherapy in resected gastric cancer: results of a single center experience. 155
Pharmacological strategies for overcoming multidrug resistance. 154
Mechanisms of methotrexate (MTX) resistance in human colon carcinoma cells DLD-1 152
Focus on Biochemical and Clinical Predictors of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma: Where Do We Stand? 152
Defining the Ideal Patient with Hepatocellular Carcinoma for Second-Line Treatment 151
Erratum: The inhibitory effects of HYDAMTIQ, a novel PARP inhibitor, on growth in human tumor cell lines with defective DNA damage response pathways (Oncology Research 25:9 (1441-1451) DOI: 10.3727/096504017X14926854178616) 150
Pharmacokinetics of melphalan (L-PAM) during hyperthermic perfusion in patients with melanoma of the limbs 148
An overview of the clinical use of cabozantinib in the treatment of advanced non-clear-cell renal cell carcinoma (NCCRCC) 148
Structural and solution chemistry, protein binding and antiproliferative profiles of gold(I)/(III) complexes bearing the saccharinato ligand. 148
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer 146
The genotype for DPYD risk variants in colorectal cancer patients and the related toxicity management costs in clinical practice. 146
Pharmacogenomic Markers of Clinical Efficacy in a Dose-Dense Therapy Regimen (R-CHOP14) in Diffuse Large B Cell Lymphoma 145
Role of ATP-binding cassette transporters in cancer initiation and progression 144
Identification of pharmacogenomic markers of 5-fluorouracil-based chemotherapy in colorectal cancer 144
Correlation between thymidylate synthase (TS) mRNA expression and TS gene promoter polymorphysms in primary colorectal cancer patients. 143
In vitro study on the safety of near infrared laser therapy in its potential application as postmastectomy lymphedema treatment 143
Thymidylate synthase and orotate phosphoribosyl-transferase gene expression and genotype as predictors for clinical outcome in colorectal cancer patients treated with 5-fluorouracil 142
Alternative approaches to overcome multidrug resistance 142
Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer 142
Correlation between thymidylate synthase (TS) mRNA expression and TS gene promoter polymorphisms in primary colorectal cancer patients 141
A potential novel drug combination for adjuvant therapy in lung cancer: reflections on an early phase of clinical development 141
Role of novel hormonal therapies in the management of non-metastatic castration-resistant prostate cancer: a literature-based meta-analysis of randomized trials 140
Mechanisms of methotrexate (MTX) resistance in human colon carcinoma cells DLD-1 139
Relationships between promoter polymorphisms in the thymidylate synthase gene and mRNA levels in colorectal cancers 139
Genomic and genetic alterations influence the progression of gastric cancer 138
Comparative genomic hybridization study of genetic changes associated with 5-fluorouracil resistance in HCT-8 colon cancer cell lines: correlations with the expression profiles 136
Totale 20.990
Salva come PNG Salva come JPEG
Categoria #
all - tutte 81.653
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 81.653
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.089 28 116 62 47 30 69 40 101 65 49 153 329
2022/20233.103 276 533 119 279 219 560 372 183 379 15 71 97
2023/20241.225 50 116 193 37 91 142 99 266 30 78 64 59
2024/20257.632 312 829 501 1.152 2.076 960 149 375 432 207 323 316
2025/20269.634 958 1.217 856 892 975 332 1.230 478 683 623 260 1.130
2026/20272 2 0 0 0 0 0 0 0 0 0 0 0
Totale 29.793